I-Mask Protocol for prevention and treatment of COVID

[Darlene]

https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Alliance-I-MASKplus-Protocol-ENGLISH.pdf

 

 

 

FRONT LINE COVID-19 CRITICAL CARE ALLIANCE PREVENTION & TREATMENT PROTOCOLS FOR COVID-19

 

PREVENTION & EARLY OUTPATIENT

TREATMENT PROTOCOL FOR COVID-19 Page 1/2

 

 

PREVENTION PROTOCOL

lvermectin1 Prevention for high risk individuals

0.2 mg/kg per dose (take with or after meals) — one dose today, repeat after 48 hours, then one dose weekly*

Post COVID-19 exposure prevention2

0.2 mg/kg per dose (take with or after meals) — one dose today, repeat after 48 hours*

Vitamin D3 1,000–3,000 IU/day Vitamin C 500–1,000 mg twice a day Quercetin 250 mg/day

Zinc 30–40 mg/day

Melatonin 6 mg before bedtime (causes drowsiness)

 

 

EARLY OUTPATIENT PROTOCOL 3

lvermectin1 0.2–0.4 mg/kg per dose (take with or after meals) — one dose daily, take for 5 days or until recovered*

Use upper dose range if: 1) in regions with more aggressive variants;

2) treatment started on or after day 5 of symptoms or in pulmonary phase; or 3) multiple comorbidities/risk factors.

Fluvoxamine 50 mg twice daily for 10–14 days.

Add to ivermectin if: 1) minimal response after 2 days of ivermectin;

2) in regions with more aggressive variants; 3) treatment started on or after day 5 of symptoms or in pulmonary phase; or 4) numerous comorbidities/risk factors. Avoid if patient is already on an SSRI.

Nasopharyngeal Steamed essential oil inhalation 3 times a day (i.e. vapo-rub)

Sanitation and/or chlorhexidine/benzydamine mouthwash gargles and Betadine nasal spray 2–3 times a day

Vitamin D3 4,000 IU/day

Vitamin C 500–1,000 mg twice a day

Quercetin 250 mg twice a day

Zinc 100 mg/day

Melatonin 10 mg before bedtime (causes drowsiness)

Aspirin 325 mg/day (unless contraindicated)

Pulse Oximeter Monitoring of oxygen saturation is recommended

(for instructions please see page 2 of this file)

 

 

For optional medicines and an overview of the developments in prevention and treatment of COVID-19, please visit www.flccc.net/optional-medicines.

 

* The dosing may be updated as further scientific studies emerge.

1    The safety of ivermectin in pregnancy has not been established. A discussion of benefits vs. risks with your provider is required prior to use, particularly in the 1st trimester.

2 To use if a household member is COVID-19 positive, or you have prolonged exposure to a COVID-19 positive patient without wearing a mask

3 For late phase — hospitalized patients — see the FLCCC’s MATH+ Hospital Treatment Protocol for COVID-19 on www.flccc.net

 

 

 

Please regard our disclaimer and further information on page 2 of this document.

flccc.net © 2020–2021 FLCCC Alliance · I-MASK+ Protocol · Version 10 · Apr 26, 2021

 

 

Behavioral Prevention

 

 

WEAR MASKS

Must wear cloth, surgical, or N95 mask (without valve) in all indoor spaces with non- household persons.

Must wear a N95 mask (with- out valve) during prolonged exposure to non-household persons in any confined, poorly ventilated area.

 

KEEP DISTANCE

Until the end of the Covid-19 crisis, we recommend keep- ing a minimum distance of approx. 2 m / 6 feet in public from people who are not from your own household.

 

WASH HANDS

We recommend, after a stay during and after outings from home (shopping, sub- way etc.), a thorough hand cleaning (20–30 sec. with soap), or also to use a hand disinfectant in between.

 

FRONT LINE COVID-19 CRITICAL CARE ALLIANCE PREVENTION & TREATMENT PROTOCOLS FOR COVID-19

 

 

 

PREVENTION & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19

 

IVERMECTIN

Summary of the Clinical Trials Evidence for Ivermectin in COVID-19

Ivermectin, an anti-parasitic medicine whose discovery won the Nobel Prize in 2015, has proven, highly potent, anti-viral and anti- inflammatory properties in laboratory studies. In the past 4 months, numerous, con-

trolled clinical trials from multiple centers and countries worldwide are reporting consistent, large improvements in COVID-19 patient outcomes when treated with ivermectin.

Our comprehensive scientific review of these referenced trials on ivermectin can be found on

www.flccc.net/flccc-ivermectin-in-the- prophylaxis-and-treatment-of-covid-19/

For a quick overview, a One-page Summary of our review on ivermectin can be found on

www.flccc.net/one-page-summary-of-the-clini- cal-trials-evidence-for-ivermectin-in-covid-19/

 

Body weight conversion (kg/lb) for ivermectin dose in prevention and treatment of COVID-19

 

Body weight Conversion (1 kg ≈ 2.2 lbs) (doses calculated per upper end of weight range)	Dose 0.2 mg/kg ≈ 0.09 mg/lb (Each tablet = 3 mg; doses rounded to nearest half tablet above)
70–90 lb	32–40 kg	8 mg	(3 tablets = 9 mg)
91–110 lb	41–50 kg	10 mg	(3.5 tablets)
111–130 lb	51–59 kg	12 mg	(4 tablets)
131–150 lb	60–68 kg	13.5 mg	(4.5 tablets)
151–170 lb	69–77 kg	15 mg	(5 tablets)
171–190 lb	78–86 kg	16 mg	(5.5 tablets)
191–210 lb	87–95 kg	18 mg	(6 tablets)
211–230 lb	96–104 kg	20 mg	(7 tablets = 21 mg)
231–250 lb	105–113 kg	22 mg	(7.5 tablets=22.5 mg)
251–270 lb	114–122 kg	24 mg	(8 tablets)
271–290 lb	123–131 kg	26 mg	(9 tablets = 27 mg)
291–310 lb	132–140 kg	28 mg	(9.5 tablets=28.5 mg)

 

 

A summary of the published data supporting the rationale for Ivermectin use in our I-MASK+ protocol can be downloaded from www.flccc.net/flccc-ivermectin-summary

For updates, references, and information on the FLCCC Alliance, the I-Mask+ Prevention & Early Outpatient Treatment Protocol for COVID-19 and the MATH+ Hospital Treatment Protocol for COVID-19, please visit our website www.flccc.net

 

flccc.net © 2020–2021 FLCCC Alliance · I-MASK+ Protocol · Version 10 · Apr 26, 2021